Distribution · GCC · Announced 11 Mar 2025
EQL Pharma → Pharmalink
EQL Pharma signed an exclusive deal for UAE-based Pharmalink to distribute Mellozzan (melatonin) across the six GCC states, for a six-figure euro fee paid in four milestones.
Parties: EQL Pharma (Sweden) → Pharmalink (United Arab Emirates)
- Deal type
- Distribution
- Value
- See terms
- Territory
- UAE, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain
- Therapeutic area
- CNS / Neurology
- Asset
- Mellozzan (melatonin)
- Announced
- 11 Mar 2025
Our analysis
Why this matters
EQL Pharma announced on 11 March 2025 an exclusive distribution agreement with Pharmalink for Mellozzan (melatonin) tablets and oral solution in the UAE, Saudi Arabia, Kuwait, Qatar, Oman and Bahrain. Mellozzan is indicated for sleep difficulties in children with ADHD and for short-term jet lag in adults. EQL receives a six-figure euro fee in four milestone payments and will hold the marketing authorisations in the region.
For BD directors at European niche-generics companies, the structure — keeping the marketing authorisation while a large regional distributor sells — preserves control of the asset in the GCC.
The full analysis is free to read with a work email on this page.